Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

thrombolysis

thrombolysis is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 1
Pipeline programs 7
News articles 0
Drug details — thrombolysis
Class
—
Route
—
Patents
1
Programs
7
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

thrombolysis is an FDA-listed pharmaceutical active ingredient.

Key facts

INN thrombolysis

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Intra-arterial thrombolysis Phase 3 · Chinese Academy of · Acute Ischemic Stroke
  2. Intravenous thrombolysis plus tirofiban Phase 3 · Chinese Academy of · Acute Ischemic Stroke
  3. Intravenous thrombolysis plus tirofiban Phase 3 · Hospital Authority · Acute Ischemic Stroke
  4. Intravenous thrombolysis + edaravone Approved · First People's Hospital · Ischemic Stroke
  5. ginkgolide Approved · First People's Hospital · Intravenous Alteplase Thrombolysis
  6. low-dose tenecteplase intravenous thrombolysis Approved · Chinese Academy of · Acute Ischemic Stroke Patients
  7. Intravenous thrombolysis Unknown · Chinese Academy of · Acute Ischemic Stroke

Related patents

Browse patents

  1. US 6191103

    Methods for enhancing thrombolysis in a mammal

    Expires Mon Feb 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is thrombolysis?

thrombolysis is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.